---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-127058"
form_type: "8-K"
ticker: "LCTX"
cik: "0000876343"
company_name: "Lineage Cell Therapeutics, Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:42:30.667046+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lineage Cell Therapeutics Q3 2024 net loss $3.0M, revenue $3.8M; OpRegen gets RMAT designation

## Summary
- Net loss $3.0M ($0.02/sh) vs $7.1M ($0.04/sh) in Q3 2023; revenue $3.8M vs $1.2M.
- Cash $32.7M expected to fund operations into Q1 2026.
- OpRegen (RG6501) received RMAT designation from FDA for geographic atrophy secondary to AMD.
- OPC1 spinal cord injury study start-up activities ongoing; ReSonance preclinical results presented.
- Operating expenses $7.6M ($3.2M R&D, $4.4M G&A), down from $7.9M in Q3 2023.

## SEC filing metadata
- accession: 0000950170-24-127058
- form_type: 8-K
- ticker: LCTX
- cik: 0000876343
- company_name: Lineage Cell Therapeutics, Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/876343/000095017024127058/0000950170-24-127058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/876343/000095017024127058/lctx-20241114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-127058
- JSON: https://secwatch.observer/filing/0000950170-24-127058.json
- Plain text: https://secwatch.observer/filing/0000950170-24-127058.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.